Figure 3.
Percentage of product-specific abusers reporting each past 30-day route of administration. Data are displayed by calendar year. Routes of administration include swallow whole (A), other oral (B), inject (C), snort (D), other (E), and smoke (F) for tapentadol extended-release (ER; circle), the abuse-deterrent formulation (ADF) ER opioid comparator group (square), and the non-ADF ER opioid comparator group (triangle). Error bars represent the 95% confidence interval.